Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 199.56B P/E 6.97 EPS this Y 42.90% Ern Qtrly Grth -98.20%
Income -2.59B Forward P/E 11.51 EPS next Y 8.70% 50D Avg Chg -6.00%
Sales 55.17B PEG 0.59 EPS past 5Y -3.07% 200D Avg Chg -17.00%
Dividend 5.00% Price/Book 1.98 EPS next 5Y 18.60% 52W High Chg -36.00%
Recommedations 2.40 Quick Ratio 0.51 Shares Outstanding 5.67B 52W Low Chg -
Insider Own 0.05% ROA 0.94% Shares Float 5.66B Beta 0.62
Inst Own 67.52% ROE -2.74% Shares Shorted/Prior 74.84M/61.73M Price 35.35
Gross Margin 60.16% Profit Margin -4.70% Avg. Volume 26,886,577 Target Price 33.34
Oper. Margin 22.40% Earnings Date Oct 29 Volume 34,241,200 Change -0.73%
About Pfizer, Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer, Inc. News
04:30 AM EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
04:25 AM 2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
11/20/24 5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
11/20/24 Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief
11/20/24 Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
11/20/24 Pfizer Announces New Chief Scientific Officer and President, Research & Development
11/20/24 Pfizer names oncology head Chris Boshoff as R&D chief
11/20/24 Pfizer Names New R&D Chief
11/20/24 Pfizer, under pressure to change, names oncology head as new R&D chief
11/20/24 Is It Time to Sell Eli Lilly and Pfizer Stocks?
11/20/24 European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
11/20/24 Flagship, Pfizer alliance yields two more startup deals
11/19/24 Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules
11/19/24 BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
11/19/24 ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
11/19/24 Pfizer (NYSE:PFE) stock falls 5.3% in past week as three-year earnings and shareholder returns continue downward trend
11/19/24 These 4 Price-to-Sales Stocks Can Supercharge Your Portfolio Growth
11/19/24 The Zacks Analyst Blog Highlights Pfizer, Newmont, Uber, Adobe and Qualcomm
11/18/24 Jim Cramer on Pfizer Inc. (PFE): ‘Still, Anything Good There, It Could Fly’
11/18/24 RFK Jr.'s HHS nomination sparks concern over pharma stocks
PFE Chatroom

User Image BourlaBeliever Posted - 39 minutes from now

$PFE more pain in store today while watching shit coins go up 20%?

User Image Dip2rip Posted - 38 minutes from now

$PFE feeling good about holding closing above $25.11 today

User Image CashFlowRatio Posted - 37 minutes from now

$PFE I don’t see not one analyst saying to sell. I do see many analysts giving PFE a Strong Buy. There are a couple Holds but no sells that I see.

User Image BigJuicy Posted - 35 minutes from now

$PFE frustration is real. Let’s try to hold around 25… under 24 is a look out below nightmare for the chart.

User Image PFElinepfrenzy1990 Posted - 32 minutes from now

$PFE - Imagine the Street letting us have over 5 green days in a month

User Image spacoli Posted - 4 minutes from now

$PFE anybody who bought in the 26is even..a low price for sure..still needs a year of the divvy to get back to even if this thing never price appreciates Where are the ficking activists??? Ct Chocula needs to go

User Image ndgt10 Posted - 8 minutes ago

$PFE Guaranteed to test that 24.11 low. If it cracks, we will see the teens.

User Image tvynis Posted - 16 minutes ago

$PFE but we have 6.7% divi :)))

User Image ndgt10 Posted - 20 minutes ago

$PFE We're caught in a value trap fellas

User Image DonCorleone77 Posted - 53 minutes ago

$ZLAB $PFE Zai Lab, Pfizer enter collaboration for Xacduro Zai Lab (ZLAB) and Pfizer (PFE) announced a strategic collaboration for the novel antibacterial drug Xacduro in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for Xacduro in mainland China. Through this collaboration, Zai Lab will leverage the commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to help accelerate access to this important therapy for patients in need in mainland China. The period of collaboration is for the imported product through November 2028, subject to early termination or extension.

User Image Escapee Posted - 1 hour ago

$PFE no PR is going to love this unless it says Albert is stepping down.

User Image mmg71 Posted - 1 hour ago

$BCTX brain cancer market size $2 bb, breast cancer market size $30 bb… and we have an effective product and MC $22 mm with $14 mm cash… $DRUG $PFE $MRK

User Image PFElinepfrenzy1990 Posted - 1 hour ago

$PFE - Yup.

User Image frontiere Posted - 2 hours ago

Interesting $ZLAB Zai Lab strat partnering $PFE Pfizer for China Abx dev — relevant somewhat to ANTX SPRO INSM etc https://www.businesswire.com/news/home/20241121825806/en/Zai-Lab-and-Pfizer-Announce-Strategic-Collaboration-on-the-Novel-Antibacterial-Drug-XACDURO%C2%AE-Sulbactam-Durlobactam

User Image Jjohne Posted - 7 hours ago

$PFE The post I published tonight implied a 11% increase in share price and yet we experience a 5% drop last week. Does that mean we should see a 15% increase soon? $PFE Over the last 30 days, the consensus EPS estimate for PFE has increased 11%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term. https://finance.yahoo.com/news/down-9-77-4-weeks-143506696.html

User Image Typecheck Posted - 8 hours ago

$PFE Another quack to head FDA but at least he is a surgeon. https://seekingalpha.com/news/4314478-marty-makary-eyed-top-contender-head-fda-under-trump

User Image Typecheck Posted - 8 hours ago

$pfe If it drops to 20, I will empty my bank account to buy more.

User Image Jjohne Posted - 8 hours ago

$PFE Over the last 30 days, the consensus EPS estimate for PFE has increased 11%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term. https://finance.yahoo.com/news/down-9-77-4-weeks-143506696.html

User Image Imonster08 Posted - 8 hours ago

$PFE Black Friday clearance sale just arrived earlier!! Bullish

User Image whiteboytrippin Posted - 9 hours ago

$PFE Come on man, they invented viagra. Show a little respect.

User Image taxplanr Posted - 9 hours ago

Senator Ron Johnson demands un-redaction of Fauci letter on youth myocarditis from C19 jab $MRNA $BNTX $PFE https://dailyclout.io/senator-ron-johnson-demands-un-redaction-of-top-level-emails-that-suggest-biden-admin-youth-myocarditis-coverup/

User Image chrisjam92 Posted - 9 hours ago

$PFE loving this opportunity.

User Image pnvoss Posted - 10 hours ago

$SPY $MRK and $PFE are the setups I like

User Image pnvoss Posted - 10 hours ago

$SPY pounding the table on $PFE and $MRK . 6 month swing. Very low rsi and mfi readings. Curling up from lows. $MRK just above 5 yr support . $PFE very oversold and low mfi readings. Both 65% undervalued to future cash flow

User Image Typecheck Posted - 10 hours ago

$PFE after market drop might be related to this: https://seekingalpha.com/news/4314379-pyxis-oncologyplummets-38-onpreliminaryphase-1-dataforcancerasset It is the WRONG reaction of course. Phase I trial on heavily treated patients may include death. It is unfortunately the normal part of ontology trials. The data is actually pretty good.

User Image Kauai_Estate Posted - 10 hours ago

$PFE getting interesting here

User Image LockStocksandBarrel Posted - 10 hours ago

$PFE RFK about to gut this one to the teens.

User Image Secretweapon Posted - 10 hours ago

$PFE

User Image MrRandyMarshMoney Posted - 11 hours ago

$PFE bounce

User Image sherifg Posted - 11 hours ago

$PFE we are down with Nvidia. Sympathy 😂

Analyst Ratings
Cantor Fitzgerald Overweight Sep 16, 24
Cantor Fitzgerald Overweight Sep 9, 24
Cantor Fitzgerald Overweight Aug 19, 24
Daiwa Capital Outperform Aug 8, 24
Barclays Equal-Weight Jul 31, 24
Wells Fargo Equal-Weight Jul 31, 24
Cantor Fitzgerald Overweight Jul 31, 24
UBS Neutral Jul 31, 24
Barclays Equal-Weight Jul 10, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gottlieb Scott Director Director Dec 15 Buy 26.4670 3,000 79,401 9,000 12/19/23
McDermott Michael Executive Vice Presi.. Executive Vice President Feb 25 Option 22.89 14,178 324,534 93,099 02/28/23
DAMICO JENNIFER B. SVP & Controller SVP & Controller Feb 25 Option 22.89 11,150 255,224 27,893 02/28/23
SUSMAN SALLY Executive Vice Presi.. Executive Vice President Feb 25 Option 22.89 72,984 1,670,604 209,179 02/28/23
Hwang Angela President, Global Bi.. President, Global Biopharma Feb 25 Option 22.89 20,273 464,049 44,541 02/28/23
JOHNSON RADY A Executive Vice Presi.. Executive Vice President Feb 25 Option 22.89 33,654 770,340 116,473 02/28/23
Hwang Angela President, Global Bi.. President, Global Biopharmaceu Feb 22 Option 30.17 57,032 1,720,655 67,027 02/24/23
SUSMAN SALLY Executive Vice Presi.. Executive Vice President Feb 22 Option 30.17 76,043 2,294,217 195,493 02/24/23
SAHNI PAYAL Executive Vice Presi.. Executive Vice President Feb 22 Option 30.17 15,209 458,856 32,671 02/24/23
McDermott Michael Executive Vice Presi.. Executive Vice President Feb 22 Option 30.17 13,307 401,472 88,957 02/24/23
JOHNSON RADY A Executive Vice Presi.. Executive Vice President Feb 22 Option 30.17 31,558 952,105 106,556 02/24/23
DAMICO JENNIFER B. SVP & Controller SVP & Controller Feb 22 Option 30.17 10,456 315,458 21,584 02/24/23
LANKLER DOUGLAS M Executive Vice Presi.. Executive Vice President Dec 14 Option 26.53 101,658 2,696,987 180,461 12/16/22
BOURLA ALBERT Chairman & CEO Chairman & CEO Dec 15 Option 26.53 222,328 5,898,362 411,890 12/16/22
DAMICO JENNIFER B. SVP & Controller SVP & Controller May 13 Sell 50.5000 4,000 202,000 15,064 05/17/22
SAHNI PAYAL Executive Vice Presi.. Executive Vice President May 13 Sell 49.8400 1,408 70,175 17,372 05/16/22
Carapezzi William R JR Executive Vice Presi.. Executive Vice President May 12 Sell 50.0000 32,908 1,645,400 38,146 05/13/22
LANKLER DOUGLAS M Executive Vice Presi.. Executive Vice President May 12 Sell 49.4100 38,273 1,891,069 78,803 05/13/22
Dolsten Mikael President R&D President R&D May 11 Sell 49.34 63,902 3,152,925 333,342 05/12/22
SUSMAN SALLY Executive Vice Presi.. Executive Vice President Feb 26 Option 25.6 63,580 1,627,648 172,880 03/01/22
DAMELIO FRANK A Executive Vice Presi.. Executive Vice President Feb 26 Option 25.6 127,160 3,255,296 649,918 03/01/22
SUSMAN SALLY Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 76,895 2,102,309 166,470 02/25/22
SAHNI PAYAL Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 13,884 379,589 29,391 02/25/22
LANKLER DOUGLAS M Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 115,342 3,153,450 181,659 02/25/22
JOHNSON RADY A Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 35,457 969,394 91,301 02/25/22
Hwang Angela Group President Group President Feb 23 Option 27.34 21,359 583,955 21,359 02/25/22
DAMELIO FRANK A Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 153,789 4,204,591 636,977 02/25/22
DAMICO JENNIFER B. SVP & Controller SVP & Controller Feb 23 Option 27.34 11,748 321,190 21,668 02/25/22
Carapezzi William R JR Executive Vice Presi.. Executive Vice President Feb 23 Option 27.34 25,632 700,779 82,914 02/25/22
YOUNG JOHN D Group President Group President Nov 11 Sell 50.09 150,000 7,513,500 312,704 11/12/21